18th Jan 2007 07:52
Deltex Medical Group PLC18 January 2007 Deltex Medical Group plc CardioQ(TM) to be evaluated by US Army in Iraq 18 January 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),the UK's leading haemodynamic monitoring company, today announces that the USarmy in Iraq are to embark on an evaluation of the Company's CardioQ monitor. Six monitors and an initial stock of probes have been ordered by the US Army foruse at a combat support hospital in Iraq. The monitors will be used to guidefluid management in trauma patients transferring to and undergoing surgery atthe hospital. Deltex Medical's chief executive, Andy Hill, commented: "The use of the CardioQ in trauma patients, whether in a combat setting orfollowing a road-traffic accident, represents a significant opportunity forDeltex Medical. Trauma patients frequently suffer from life-threatening blood-loss, eitherinternally or externally, that requires rapid assessment and immediateintervention. The CardioQ looks directly at blood flow, rather than relying onless sensitive pressure-based parameters, which gives it a fundamentaltechnological advantage over other monitoring systems and makes it ideallysuited for this application. The CardioQ is the only haemodynamic monitor proven to improve outcomes whenused during surgery, where similar rapid changes in haemodynamics are seen. Wefully expect that this work by the US army will report similar improvements inoutcome in patients undergoing surgery for trauma based on this work." For further information, please contact:- Deltex Medical Group plc Tel: 01243 774 837 Nigel Keen, [email protected] Andy Hill, Chief [email protected] Ewan Phillips, Finance [email protected] Gavin Anderson & Company Tel: 0207 554 1400 Deborah Walter [email protected] Robert Speed [email protected] Marie Cairney [email protected] Charles Stanley Securities Tel: 0207 149 6457 Philip Davies [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical